tbuckley/cabot-search huggingface dataset:
Dermatan sulfate activates nuclear factor-κb and induces endothelial and circulating intercellular adhesion molecule-1
Authors: Stanley F. Penc, Bohdan Pomahac, Elof Eriksson, Michael Detmar, Richard L. Gallo
Journal: Journal of Clinical Investigation (1999)

Proteoglycans (PGs) can influence cell behaviors through binding events mediated by their glycosaminoglycan (GAG) chains. This report demonstrates that chondroitin sulfate B, also known as dermatan sulfate (DS), a major GAG released during the inflammatory phase of wound repair, directly activates cells at the physiologic concentrations of DS found in wounds. Cultured human dermal microvascular endothelial cells exposed to DS responded with rapid nuclear translocation of nuclear factor-κB (NF-κB), increased expression of intercellular adhesion molecule-1 (ICAM-1) mRNA, and increased ICAM-1 cell surface protein. Heparan sulfate and chondroitin sulfates A and C had no effect on activation of NF-κB or induction of ICAM-1. Inhibition of NF-κB activation blocked the effect of DS. The increase in cell surface ICAM-1 did not involve TNF-α or IL-1 release by endothelial cells, but it was facilitated by autocrine factors whose release was initiated by DS. The ICAM-1–inductive activity of DS was confirmed in vivo. Injection of DS, but not heparin or other chondroitin sulfates, into mice greatly increased circulating levels of soluble ICAM. These data provide evidence that DS, but not other GAGs, initiates a previously unrecognized cell signaling event that can act during the response to injury.
<i>Scedosporium apiospermum</i> Soft Tissue Infection As the Initial Presentation of Acute Myeloid Leukemia: A Case Report
Authors: Pamela B. Allen, Rima Koka, Michael E. Kleinberg, Maria R. Baer
Journal: Journal of Clinical Oncology (2013)

Case ReportAn 82-year-old woman presented with a nonhealing ulcer of her right leg as the first manifestation of acute leukemia.She had bumped her right leg while gardening and developed an ulcer that initially crusted but subsequently evolved a necrotic center.Several weeks later, the patient saw her primary care physician and was treated empirically with cephalexin and then trimethoprim and sulfamethoxazole with no improvement.She was found to have pancytopenia including severe neutropenia.Bone marrow aspirate (Fig 1A ) showed 93% blasts, and a biopsy (Figs 1B [low power] and 1C [high power]) demonstrated a markedly hypercellular marrow composed primarily of immature myeloid cells with a marked decrease in cells of erythroid and megakaryocytic lineages.A diagnosis of acute myeloid leukemia (AML), French-American-British type M0, was made.The marrow karyotype was normal, and a molecular analysis demonstrated wildtype FLT-3 and NPM-1.Treatment was initiated with decitabine 20 mg/m 2 per day intravenously for 10 days. 1 A biopsy of the ulcer was performed on admission, and pathology showed septated hyphae.While awaiting definitive speciation from the culture, the patient was treated with 6 mg/kg voriconazole oral loading dose for two doses followed by 4 mg/kg oral (200-mg total dose) twice a day in addition to antibacterial agents for neutropenic fever.Tendayslatertheulcerandsubcutaneoustissuewereextensivelydebrided to clean margins (Fig 2A).Pathology from the debridement revealed subcutaneous acute inflammation; hemorrhage; edema; and extensive diffuse epidermal, dermal, and subcutaneous necrosis with septated sporulating fungal hyphae (Fig 3A; periodic acid-Schiff stain), suggestive of Aspergillus, at all levels of the tissue with focal vascular invasion.Grocott's methenamine silver stain of the ulcer showed invasive fungal organisms (Fig3B).Magneticresonanceimaging(MRI)ofthelegatthattimedidnot
A pressure profile for elastic stockings.
Authors: J Horner, L C Lowth, A N Nicolaides
Journal: BMJ (1980)

Special equipment to measure the circumferential compression exerted by an elastic stocking was used to determine the "pressure-girth profiles" of several types of elastic stocking. Once the pressure-girth profile has been determined, the pressure exerted at the ankle, calf, and thigh can be predicted for any size of limb without further pressure measurements. An excellent correlation (r = 0.96) was obtained when this method was compared with another well-established one of measuring the pressures exerted by stockings. The method has several potential applications in quality control during stocking manufacture and, clinically, in determining whether a stocking exerts a graduated pressure on a particular limb.
Stage Is Not a Reliable Indicator of Tumor Volume in Non-small Cell Lung Cancer: A Preliminary Analysis of the Trans-Tasman Radiation Oncology Group 99-05 Database
Authors: David L. Ball, Richard Fisher, Bryan Burmeister, Peter Graham, David Joseph, Michael Penniment, Hedley Krawitz, Greg Wheeler, Michael Poulsen, Shalini Vinod, Bev McClure
Journal: Journal of Thoracic Oncology (2006)
IMMUNE RESPONSES TO TREATMENT WITH NATURAL AND SYNTHETIC ACTH IN BRONCHIAL ASTHMA
Authors: KJELL‐ORVAR PEGELOW, JONAS JONSSON
Journal: Allergy (1975)

Two comparable groups of asthmatics each with 10 patients were treated during 2 years at scheduled intervals with either natural or synthetic ACTH up to a total dose of 2000-95-- IU. All patients had previously been given the natural but never the synthetic hormone. Intradermal tests with natural and synthetic ACTH were performed before treatment and after 1, 12 and 24 months. Serum samples were also taken on these occasions and analysed for antibodies against ACTH, vasopressin and porcine gamma-globulin. No sign of clinical allergy to ACTH was noted in any of the patients during the 2-year period. The incidence of intradermal reactions against natural ACTH was high at the onset of treatment but was not increased by treatment with either synthetic or natural ACTH, while the reactivity rate against synthetic ACTH was increased after both types of treatment. The incidence of IgE reactions against synthetic ACTH at the 20 U/ml level was significantly increased after 12 months' treatment with either natural or synthetic hormone. A high incidence of low-titered agglutinating antibodies against natural or synthetic ACTH was demonstrated before treatment in both the groups, but no significant change in incidence or mean titre against natural or synthetic ACTH or porcine gamma-globulin was noted during treatment with the natural or the synthetic preparation. A few patients, however, did display an increased agglutinating titre against ACTH after 12 months' treatment. Rather unexpectedly, most sera reacting with ACTH were found to react also with vasopressin and a significant increase of the incidence of these reactions and of the titres occurred during the treatment with synthetic as well as with natural ACTH. Two cases have been examined in detail, one because of a fulminant shock after synthetic ACTH and the other because of very high antibody titres without clinical symptoms of ACTH allergy.
Malignant Bladder Tumors in a Man and His Three Sons
Authors: Joseph F. Fraumeni
Journal: JAMA (1967)

Bladder carcinoma developed in a man and his three sons. Chemical exposures suspected in bladder carcinogenesis could not be identified in the environment of this family, so a genetically controlled mechanism was considered. Urinary tryptophan metabolites, which have been implicated in the origin of some forms of bladder cancer, were normal in the two survivors with this neoplasm.
Management of Fibromyalgia
Authors: Hideto Akama
Journal: Annals of Internal Medicine (2000)

Letters20 June 2000Management of FibromyalgiaHideto Akama, MDHideto Akama, MDTokyo Women's Medical University; Tokyo 162-0054, Japan (Akama)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-132-12-200006200-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Leventhal (1) states in the abstract of his paper that trigger-point injections of analgesics may be helpful in the management of pain associated with fibromyalgia. In the Conclusion section of the paper, however, he mentions “tender point injections.” “Tender points” and “trigger points” are distinct clinical entities (2, 3), although the two phenomena may coexist in the same patient and overlap syndromes can occur (2). “Tender points” are areas of tenderness occurring in muscle, muscle–tendon junctions, bursa, or fat pads. Tender points are considered characteristic of fibromyalgia, especially when they occur in a widespread manner (2). On ...References1. Leventhal LJ. Management of fibromyalgia. Ann Intern Med. 1999;131:850-8. LinkGoogle Scholar2. Borg-Stein J, Stein J. Trigger points and tender points: one and the same? Does injection treatment help? Rheum Dis Clin North Am. 1996;22:305-22. CrossrefMedlineGoogle Scholar3. Schneider MJ. Tender points/fibromyalgia vs. trigger points/myofascial pain syndrome: a need for clarity in terminology and differential diagnosis. J Manipulative Physiol Ther. 1995;18:398-406. MedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Hideto Akama, MDAffiliations: Tokyo Women's Medical University; Tokyo 162-0054, Japan (Akama) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoManagement of Fibromyalgia Lawrence J. Leventhal Management of Fibromyalgia Lawrence J. Cohn Management of Fibromyalgia Lawrence J. Leventhal Management of Fibromyalgia Frederick Wolfe Management of Fibromyalgia Arthur Huppert Management of Fibromyalgia Norman Muilenburg Metrics Cited byParental rearing style, premorbid personality, mental health, and quality of life in chronic regional pain: A causal analysisFibromyalgia 20 June 2000Volume 132, Issue 12Page: 1005KeywordsAdipose tissueAnalgesicsFibromyalgiaMusclesMyalgiaMyofascial painOverlap syndromePain management ePublished: 15 August 2000 Issue Published: 20 June 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Chronic Fatigue Syndrome
Authors: James I. Hudson
Journal: JAMA (1991)

To the Editor. —  Gold et al 1 reported that patients with chronic fatigue displayed no evidence of ongoing EBV infection but showed a strikingly high prevalence of depressive illness. We offer further evidence to support the latter finding.  Chronic fatigue syndrome has been shown to overlap significantly with fibromyalgia, 2,3 an idiopathic rheumatic condition characterized by chronic generalized pain, multiple tender points, and, frequently, persistent fatigue. We recently interviewed 33 consecutive patients with fibromyalgia using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition (SCID), 4 a structured interview designed to assess the prevalence of current or past major psychiatric disorders. We also administered a supplemental interview in SCID format assessing chronic fatigue syndrome, irritable bowel syndrome, migraine, and narcolepsy.  Of the 33 patients with fibromyalgia, 14 (42%) met the full interview criteria for chronic fatigue syndrome, and nine others (27%) fell only
The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domains
Authors: J A Marteijn, L T van der Meer, J J Smit, S M Noordermeer, W Wissink, P Jansen, H G Swarts, R G Hibbert, T de Witte, T K Sixma, J H Jansen, B A van der Reijden
Journal: Leukemia (2009)
A clinical trials register for Europe
Authors: A. Tonks
Journal: BMJ (2002)

For more than a decade, clinical trialists and their sponsors have been saying that they want all controlled clinical trials tagged and listed somewhere while they are in progress—preferably on an international register that's simple to use, searchable, and free to anyone who wants to know who is studying what and where. No one doubts that registering ongoing controlled trials is a good idea. The Americans have made an excellent start with their publicly funded register(http://www.clinicaltrials.gov/>).1 And the United Kingdom's Medical Research Council and the NHS Research and Development Programme have made important progress through a meta-register of controlled trials (http://www.controlled-trials.com/>), established by Current Controlled Trials, a publisher. Why has it not happened more widely in Europe? Last year the European Science Foundation, an umbrella organisation, advised all its member organisations to register controlled trials through http://www.controlled-trials.com/>and to assign each of them a unique identifier—an international standard randomised controlled trial number (ISRCTN).2 Last month, the foundation hosted a meeting in Frankfurt to review progress, and more importantly, to urge members to stop talking and do something.

The compelling arguments that started this debate 10 years ago remain the same: 3 4 The international research effort is chaotic. It is impossible to …
Organ matching website says it will operate within the law
Authors: M. Limb
Journal: BMJ (2012)

The founders of a US organisation that offers to “match” people seeking organ transplants with potential living donors in the UK have sought to reassure regulators they will work within the law.

Paul Dooley, chief executive of Boston based MatchingDonors.com, has written to the UK Human Tissue Authority to explain how a UK version of the website (www.matchingdonors.co.uk) would operate after its launch last week.

He said he agreed “wholeheartedly” with the authority’s position that for transplants to go ahead legally there must be consent and no reward could be given, offered, or sought for the supply of an organ.

He said his staff would monitor email interactions to help “deter potential misdoings.”

The letter says, “Before launching in the UK MatchingDonors.com has been working closely with the …
<i>Weisses Blut</i>—Leukapheresis in acute leukemia
Authors: Michael H.A. Roehrl, W. Sunny Dzik
Journal: American Journal of Hematology (2007)

A 30-year-old woman presented to the Emergency Department with symptoms of fatigue and malaise for 2 weeks.She described occasional frontal and occipital headaches but had no focal neurologic complaints.She had increasing scattered bruising on her lower legs and thighs and noticed the onset of mild vision changes and Image.
Arsenic pollution at Obuasi Goldmine, town, and surrounding countryside.
Authors: S K Amasa
Journal: Environmental Health Perspectives (1975)

Human hair samples from mine workers and Obuasi citizens; various food items; drinking and washing water from Obuasi town; vegetation and soils from the countryside bordering on the goldmine; and geological materials from the mining process were collected and analyzed by volumetric, gravimetric, colorimetric, and neutron activation methods in order to assess the degree of arsenic pollution brought about as a result of the goldmining operations at Obuasi.
Estimation of myocardial infarct size with ultrasonic tissue characterization.
Authors: K B Sagar, L R Pelc, T L Rhyne, J Howard, D C Warltier
Journal: Circulation (1991)

BACKGROUND Ultrasonic tissue characterization (UTC) can distinguish normal from infarcted myocardium. Infarcted myocardium shows an increase in integrated backscatter and loss of cardiac cycle-dependent variation in backscatter. The cyclic variation of backscatter is closely related to regional myocardial contractile function; the latter is a marker of myocardial ischemia. The present study was designed to test the hypothesis that intramural cyclic variation of backscatter can map and estimate infarct size. METHODS AND RESULTS Transmural myocardial infarction was produced in 12 anesthetized, open-chest dogs by total occlusion of the left anterior descending coronary artery for 4 hours. A real-time ultrasonic tissue characterization instrument, which graphically displays integrated backscatter Rayleigh 5, cardiac cycle-dependent variation, and patterns of cyclic variation in backscatter, was used to map infarct size and area at risk of infarction. Staining with 2,3,4-triphenyltetrazolium chloride (TTC) and Patent Blue Dye was used to estimate infarct size and the area at risk, respectively. The ratio of infarct size to area at risk of infarction determined with UTC correlated well with that determined with TCC (r = 0.862, y = 23.7 +/- 0.792x). Correlation coefficients for infarct size and area at risk were also good (r = 0.736, y = 12.3 +/- 737x for infarct size and r = 0.714, y = 5.80 +/- 1.012x for area at risk). However, UTC underestimated both infarct size and area at risk. CONCLUSIONS Ultrasonic tissue characterization may provide a reliable, noninvasive method to estimate myocardial infarct size.
Coronary Thrombolysis: A Double-Edged Sword?
Authors: Kenneth M. Kessler
Journal: Annals of Internal Medicine (1999)

Letters6 July 1999Coronary Thrombolysis: A Double-Edged Sword?Kenneth M. Kessler, MDKenneth M. Kessler, MDUniversity of Miami School of Medicine; Miami, FL 33101 (Kessler)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-1-199907060-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Gurwitz and colleagues (1) present important clinical information showing that the risk for hemorrhagic stroke increases as one moves from a clinical trial setting to a usual-care setting. These findings are all the more disturbing if one considers the following: First, the benefit (absolute risk reduction) of thrombolytic therapy is itself small, in absolute numbers ranging from 3% to 6%. Therefore, even a small, in absolute terms, increase in risk can rapidly undermine benefit because that benefit is also small. Second, with respect to mortality, only patients who would have died without thrombolytic therapy (10% to 15%) ...Reference1. Gurwitz JH, Gore JM, Goldberg RJ, Barron HV, Breen T, Rundle AC, et al . Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Ann Intern Med. 1998;129:597-604. LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: Kenneth M. Kessler, MDAffiliations: University of Miami School of Medicine; Miami, FL 33101 (Kessler) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRisk for Intracranial Hemorrhage after Tissue Plasminogen Activator Treatment for Acute Myocardial Infarction Jerry H. Gurwitz , Joel M. Gore , Robert J. Goldberg , Hal V. Barron , Timothy Breen , Amy Chen Rundle , Michael A. Sloan , William French , and William J. Rogers Coronary Thrombolysis: A Double-Edged Sword? Jerry H. Gurwitz , Robert J. Goldberg , and Joel M. Gore Metrics 6 July 1999Volume 131, Issue 1Page: 71KeywordsAbsolute risk reductionClinical trialsHemorrhagic strokeMortality ePublished: 15 August 2000 Issue Published: 6 July 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti-viral activity
Authors: Gary A. Levy, Gord Adamson, James M. Phillips, Louise A. Scrocchi, Laisum Fung, Pieter Biessels, Nancy F. Ng, Anand Ghanekar, Andrea Rowe, Max Xuezhong Ma, Adam Levy, Cheryl Koscik, William He, Reginald Gorczynski, Steve Brookes, Caroline Woods, Ian D. McGilvray, David Bell
Journal: Hepatology (2006)

Side effects of interferon-ribavirin combination therapy limit the sustained viral response achievable in hepatitis C virus (HCV) patients. Coupling ribavirin to macromolecular carriers that target the drug to the liver would reduce systemic complications. The aim of this study was to evaluate the efficacy of a hemoglobin-ribavirin conjugate (HRC 203) in murine hepatitis virus strain 3 (MHV-3) induced viral hepatitis. HRC 203 had greater anti-viral activity on both isolated hepatocytes and macrophages, whereas both ribavirin and HRC 203 inhibited production of the pro-inflammatory cytokines interferon gamma (IFN-gamma) and tumor necrosis factor alpha (TNF-alpha) by macrophages. In vivo, untreated MHV-3-infected mice all developed clinical and biochemical signs of acute viral hepatitis and died by day 4 post infection. Livers recovered from untreated infected mice showed greater than 90% necrosis. In contrast, survival was enhanced in both ribavirin- and HRC 203-treated mice with a marked reduction in biochemical [ALT(max) 964 +/- 128 IU/L (ribavirin); 848 +/- 212 IU/L (HRC 203)] and histological evidence of hepatic necrosis (<10% in ribavirin/HRC 203 vs. 90% in untreated controls). Clinically, HRC 203-treated mice behaved normally, in contrast to ribavirin-treated mice, which developed lethargy and abnormal fur texture. In conclusion, targeted delivery of ribavirin to the liver alters the course of MHV-3 infection as demonstrated by prolonged survival, improved behavior, and reduced signs of histologically evident disease, as well as inhibition of viral replication and production of inflammatory cytokines in vitro.
Rehabilitation of the Patient with Respiratory Disease
Authors: Thomas L. Petty
Journal: Annals of Internal Medicine (1999)

Medical Writings: Book Notes7 September 1999Rehabilitation of the Patient with Respiratory DiseaseThomas L. Petty, MDThomas L. Petty, MDHealthONE, University of Colorado Health Sciences Center, Denver, Colorado. (Petty)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-131-5-199909070-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Cherniack NS, Altose MD, Homma I; eds. 724 pages. New York: McGraw-Hill; 1999. $155.00. ISBN 0070116490. Order phone 800-262-4729.Field of medicine: Pulmonary disease and rehabilitation.Format: Hardcover book.Audience: Physicians in pulmonary medicine and rehabilitation, nurses, and respiratory therapists.Purpose: To present a detailed scientific basis for pulmonary rehabilitation with an emphasis on physiologic principles and current therapies and technologies.Content: The first three sections cover physiologic foundations, pathophysiology, and patient assessment. Part four deals with specific therapeutic approaches to diseases that result in pulmonary insufficiency. Part five discusses management of specific disease states. Part six presents psychosocial considerations, ... Author, Article, and Disclosure InformationAffiliations: HealthONE, University of Colorado Health Sciences Center, Denver, Colorado. (Petty) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 7 September 1999Volume 131, Issue 5Page: 399-400KeywordsChronic obstructive pulmonary diseaseExercise therapyNeuromuscular diseasesNutritionOxygenPulmonary diseasesQuality of lifeRehabilitation medicineSmoking cessationVentilators Issue Published: 7 September 1999 Copyright & PermissionsCopyright © 1999 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...